Literature DB >> 26307636

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.

Dan Yan1, Marco Weisshaar1, Kristen Lamb1, Hokyung K Chung2, Michael Z Lin3,4, Richard K Plemper1.   

Abstract

Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26307636      PMCID: PMC4719150          DOI: 10.1021/acs.biochem.5b00623

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  82 in total

1.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

2.  Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.

Authors:  Oxana V Denisova; Laura Kakkola; Lin Feng; Jakob Stenman; Ashwini Nagaraj; Johanna Lampe; Bhagwan Yadav; Tero Aittokallio; Pasi Kaukinen; Tero Ahola; Suvi Kuivanen; Olli Vapalahti; Anu Kantele; Janne Tynell; Ilkka Julkunen; Hannimari Kallio-Kokko; Henrik Paavilainen; Veijo Hukkanen; Richard M Elliott; Jef K De Brabander; Xavier Saelens; Denis E Kainov
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

3.  GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.

Authors:  Grushenka H I Wolfgang; Riri Shibata; Jianying Wang; Adrian S Ray; Sylvia Wu; Edward Doerrfler; Hans Reiser; William A Lee; Gabriel Birkus; Neil D Christensen; Graciela Andrei; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

4.  Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.

Authors:  Dominic Salerno; Muneer G Hasham; Renée Marshall; Judit Garriga; Alexander Y Tsygankov; Xavier Graña
Journal:  Gene       Date:  2007-09-19       Impact factor: 3.688

5.  In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies.

Authors:  Nicholas S Heaton; Victor H Leyva-Grado; Gene S Tan; Dirk Eggink; Rong Hai; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

6.  An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model.

Authors:  Stefanie A Krumm; Dan Yan; Elise S Hovingh; Taylor J Evers; Theresa Enkirch; G Prabhakar Reddy; Aiming Sun; Manohar T Saindane; Richard F Arrendale; George Painter; Dennis C Liotta; Michael G Natchus; Veronika von Messling; Richard K Plemper
Journal:  Sci Transl Med       Date:  2014-04-16       Impact factor: 17.956

Review 7.  Synergizing vaccinations with therapeutics for measles eradication.

Authors:  Richard K Plemper; Anthea L Hammond
Journal:  Expert Opin Drug Discov       Date:  2013-12-05       Impact factor: 6.098

8.  Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.

Authors:  Parthiv J Mahadevia; Anthony S Masaquel; Mark J Polak; Leonard B Weiner
Journal:  J Med Econ       Date:  2012-05-10       Impact factor: 2.448

9.  Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein.

Authors:  Zhitao Wan; Xulin Chen
Journal:  Retrovirology       Date:  2014-10-17       Impact factor: 4.602

10.  Morphine stimulates cell migration of oral epithelial cells by delta-opioid receptor activation.

Authors:  Nada Charbaji; Monika Schäfer-Korting; Sarah Küchler
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

View more
  23 in total

1.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex.

Authors:  Alberto Jiménez-Somarribas; Shuli Mao; Jeong-Joong Yoon; Marco Weisshaar; Robert M Cox; Jose R Marengo; Deborah G Mitchell; Zachary P Morehouse; Dan Yan; Ivan Solis; Dennis C Liotta; Michael G Natchus; Richard K Plemper
Journal:  J Med Chem       Date:  2017-03-13       Impact factor: 7.446

3.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 4.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

Review 5.  Development and application of bioluminescence imaging for the influenza A virus.

Authors:  Weiqi Pan; Ji Dong; Peihai Chen; Beiwu Zhang; Zhixia Li; Ling Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Engineered Small-Molecule Control of Influenza A Virus Replication.

Authors:  Elizabeth J Fay; Stephanie L Aron; Ian A Stone; Barbara M Waring; Richard K Plemper; Ryan A Langlois
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

7.  Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening.

Authors:  Marco Weisshaar; Robert Cox; Zachary Morehouse; Shiva Kumar Kyasa; Dan Yan; Phil Oberacker; Shuli Mao; Jennifer E Golden; Anice C Lowen; Michael G Natchus; Richard K Plemper
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

8.  Directed Evolution of an Influenza Reporter Virus To Restore Replication and Virulence and Enhance Noninvasive Bioluminescence Imaging in Mice.

Authors:  Hui Cai; Meisui Liu; Charles J Russell
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

9.  Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Authors:  Jeong-Joong Yoon; Mart Toots; Sujin Lee; Myung-Eun Lee; Barbara Ludeke; Jasmina M Luczo; Ketaki Ganti; Robert M Cox; Zachary M Sticher; Vindya Edpuganti; Deborah G Mitchell; Mark A Lockwood; Alexander A Kolykhalov; Alexander L Greninger; Martin L Moore; George R Painter; Anice C Lowen; Stephen M Tompkins; Rachel Fearns; Michael G Natchus; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Structure-guided design of small-molecule therapeutics against RSV disease.

Authors:  Robert Cox; Richard K Plemper
Journal:  Expert Opin Drug Discov       Date:  2016-04-21       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.